127 related articles for article (PubMed ID: 35307850)
1. An open-label, phase 1, randomized, three treatments, three-period, crossover, relative bioavailability study of CC-292, a potent and orally available inhibitor of bruton tyrosine kinase.
Cheng Y; Liu L; Xue Y; Zhou S; Li Y
J Clin Pharm Ther; 2022 Aug; 47(8):1186-1193. PubMed ID: 35307850
[TBL] [
